The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial.
 
John Robert Mackey
Consulting or Advisory Role - ImClone Systems; Roche/Genentech
Research Funding - ImClone Systems; Roche/Genentech
 
Oleg N. Lipatov
No Relationships to Disclose
 
Miguel Martin
Honoraria - Roche Pharma AG
Consulting or Advisory Role - Roche Pharma AG
 
Marc Webster
Honoraria - Eisai; Novartis
Consulting or Advisory Role - Amgen; Eisai; Novartis; Roche Pharma AG
 
Roberto Hegg
No Relationships to Disclose
 
Sunil Verma
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Lilly; Novartis; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Sanofi
 
Manuel Ramos Vazquez
No Relationships to Disclose
 
Rodrigo Fresco
No Relationships to Disclose
 
Francois Thireau
No Relationships to Disclose
 
Vincent Houé
No Relationships to Disclose
 
Michael F. Press
Honoraria - Amgen; Biocartis; Cepheid; Dako; GlaxoSmithKline; Halozyme; NanoString Technologies; OncoMed; Puma Biotechnology
Consulting or Advisory Role - Amgen; Biocartis; Cepheid; Dako; GlaxoSmithKline; Halozyme; NanoString Technologies; OncoMed; Puma Biotechnology
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Dako; Dendreon
 
Ashok Narasimhan
No Relationships to Disclose
 
Sambasivarao Damaraju
Research Funding - Lilly/ImClone